Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Regimen shows promise as salvage for classical HL

Publish date:: February 22, 2019

Key clinical point: Brentuximab vedotin plus ifosfamide, gemcitabine, and vinorelbine (BV-IGEV) appears effective as salvage for patients with relapsed/refractory classical Hodgkin lymphoma.

Major finding: Of 28 patients, 27 responded to BV-IGEV.

Study details: A retrospective study of 28 patients.

Disclosures: The authors reported having no conflicts of interest.

Citation:

Abuelgasim KA et al. Bone Marrow Transplant. 2019 Jan 30. doi: 10.1038/s41409-019-0454-z.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Hodgkin Lymphoma

Childhood Hodgkin survivors have neurocognitive impairment,

Survey quantifies COVID-19’s impact on oncology,

Early screening may halve breast cancer mortality in childhood cancer survivors,

Eczema may increase lymphoma risk, cohort studies suggest,

Cancer risk elevated in hidradenitis suppurativa patients,